Abbreviations: FTI, farnesyltransferase inhibitor; MNU, methyl-nitroso-urea; PCR, Polymerase Chain Reaction; PCR-RFLP, PCR-restriction fragment length polymorphism.
profound regression, with nearly 90% showing complete regressions within 4 weeks. In contrast, the non Ha-ras mutation-bearing tumors yielded a more variable response although roughly half of the non Ha-ras mutations tumors underwent significant regression. These results show that although all tumors appear to respond to the FTI inhibitor the tumors with Ha-ras mutations were exquisitely sensitive. We employed a microarray approach to define potential targets and the mechanism of action of R115777 in Ha-ras positive or negative tumors following treatment with FTI. In addition we determined whether gene expression prior to FTI treatment can be used to differentiate highly sensitive tumors (Ha-ras positive) and tumors with variably sensitivity (Ha-ras negative). Untreated or FTI treated (4 days at 50 mg/KgBW) tumors (Ha-ras positive or negative) were examined using oligonucleotide arrays. A significant number of genes were differentially expressed in control rat mammary tumors with or without an activated Ha-ras mutation, suggesting that a microarray analysis might differentiate highly sensitive and variably sensitive tumors. Most of the genes whose expressions were modulated by FTI in tumors were independent of Ha-ras status. and were presumably modulated by effects on farnesylation of proteins other than Ha-ras. However treatment of Ha-ras mutated mammary tumors with R155777 results in preferential modulation of genes involved in ras-MAP kinase signal transduction pathway and in decreased expression of many genes involved with cell proliferation. In contrast, several classes of genes that are altered in rat mammary tumors without an activated Ha-ras, suggesting that non-ras targets are involved. Ras pathway related genes, p53, WT1, and PCNA were preferentially modulated in Ha-ras activated tumors, whereas modulation of genes in the G-protein pathway, various cytochrome p450s, and RB1 are involved in Ha-ras negative tumors. Elucidation of gene expression changes in FTI treated or control rat mammary adenocarcinomas will help to identify potential pharmacodynamic markers of FTI tretment as well as potential molecular targets of R115777 and other farnesyltransferase inhibitors.
Introduction:
The Ras GTPase gene(s) are involved in signaling a wide range of growth factors and growth factor receptors including EGFR, Neu, FGF and VEGF (1) . Reflecting its central role in determining cell proliferation, Ras is one of the most commonly mutated human at Pennsylvania State University on February 20, 2013 http://carcin.oxfordjournals.org/ Downloaded from oncogenes (2) . This family of genes is mutated in a substantial percentage of the two greatest cancer killers in humans (lung and colon) and appears to be mutated in virtually every pancreatic cancer; implying that its mutation may be mandatory for this form of cancer. The Ras genes were identified almost 35 years ago since it proved to be the primary oncogene in two of the "classic oncogenic viruses in mice specifically Ki-Ras in Ki MuSV (Kirsten murine sarcoma virus) and Ha-ras in HSV (Harvey sarcoma virus) (3) (4) (5) . The Ras oncogene proteins must be prenylated in order to be translocated to the cell membrane and become functional (1) . Since their activation is dependent upon this translocation, blocking the prenylation of these proteins has become a major potential focus for pharmacologically intervening in Ras activation. The agent which we have employed is R115777 which is an orally bioavailable imidazole analog that blocks prenylation of Ha-ras, but not K-ras and Nras (6) . Inhibition of the growth of tumors that harbor K-ras or N-ras mutations indicated that FTIs also target other proteins important in oncogenesis. Like most of the FTI inhibitors it requires significantly higher doses to block the farnesylation of Ki-ras (7) . In view of the ability of FTI to inhibit various cancers with Ki-ras mutations, or with no Ras mutations at all investigators have searched for alternative proteins which are prenylated and might be candidate target genes e.g. Rho B, CNEB E/F, and Rheb (1).
The chemically induced models of mammary carcinogenesis were initially developed almost 40 years ago by Huggins and co-workers (8, 9) . Female Sprague-Dawley rats develop multiple hormonally responsive mammary cancers, starting within 5 weeks of the time that they are administered the carcinogen. In the MNU model, roughly 50% of the resulting tumors have mutations in codon 12 of Ha-ras (10, 11) . In contrast to this significant contribution of Ras mutations to tumorigenesis in the rat models of mammary cancer, mutations in this family of genes are infrequently observed in human breast cancer.
However, increased expression of Ras itself or of MAP kinase (one of its downstream effectors elements) is observed in roughly 50% of breast cancers (12) . Furthermore, upstream effectors of the ras proteins e.g. EGFR and HER2/Neu are over expressed in many human mammary tumors. The appeal of this model is that the tumors arise in situ, that roughly 50% of the tumors have mutation and that the mutations are focal. In contrast transgenic mice overexpressing ras typically have these genes overexpressed in a high percentage of cells in the breast (13) . Furthermore, in the case of the transgenic, the fact that at Pennsylvania State University on February 20, 2013 http://carcin.oxfordjournals.org/ Downloaded from the overexpression is the primary oncogenic event almost determines by itself that inhibition of the activating gene will result in profound effects on tumors.
We, therefore, examined the therapeutic effect of the FTI inhibitor in this model to determine if FTI is effective in this model system, and if therapeutic efficacy is much more striking in tumors with mutation in Ha-ras. Based on the results of this experiment which demonstrate exquisite sensitivity in Ha-ras mutation positive tumors, we employed genomic approaches to 1) define genes whose expression are modulated and may contribute to the mechanism of action of R115777 in Ha-ras mutation positive or negative tumors; 2) determine whether gene expression differences can be used to differentiate exquisitely sensitive tumors (Ha-ras positive) and variably sensitive tumors (Ha-ras negative) prior to FTI treatment.
Materials and Methods:

Chemicals
Chemicals and other materials were obtained as follows: corn oil was purchased 
Chemotherapeutic studies
Generation of MNU induced tumors and their use in therapeutic models have been previously described (11, 14) . Female Sprague Dawley rats were obtained at 28 days of age and housed in polycarbonate cages (5 rats/cage). At 50 days of age the rats received a single i.v. injection of MNU (50 mg/KgBW) via the jugular vein. Rats were then examined 2× per week for the formation of palpable lesions. Palpable lesions began to arise beginning roughly five weeks post MNU. When a tumor reached a volume of roughly 150-300 mm 3 , as measured by calipers, animals were anesthetized and mammary tumors were biopsied. The resulting biopsies were placed into liquid nitrogen and the Ki-ras and Ha-ras mutation status of the tumors was examined employing the sequencing procedures outlined below. Tumor 
Analysis of Ras Mutations by PCR-Direct Sequencing
DNA was isolated from rat mammary tumors using the TRIzol (Gibco BRL).
Sequences of PCR primers for the exon 1 of the Ki-ras and Ha-ras gene were described previously (11) . The 12th codon mutations were analyzed with an ABI PRISM 3700 DNA analyzer (PE Applied Biosystems, Foster City, CA). The primers for Ki-ras gene are: 
RNA Isolation
Random selected 8 rat mammary tumors treated with R115777 or with vehicle control were microdissected to remove surrounding stroma cells before being used for RNA isolation. Generally, two 5-micron frozen sections (with 50-100 microns distance between)
were cut using a cryostat microtome. and UTP were used in the reaction together with unlabeled NTPs. After the reaction, the unincorporated nucleotides were removed using RNeasy columns (Qiagen).
Array Hybridization and Scanning
Approximately 10 µg of cRNA was fragmented at 94°C for 35 min in a fragmentation buffer containing 40 mM Tris-acetate (pH 8.1), 100 mM KOAc, and 30 mM
MgOAc. Prior to hybridization, the fragmented cRNA was placed in a 6× SSPE-T hybridization buffer (1 M NaCl, 10 mM Tris (pH 7.6), and 0.005% Triton) and heated to 95°C for 5 min and, subsequently, to 40°C for 5 min before loading onto the Affymetrix probe array cartridge. The probe array was then incubated for 16 h at 40°C at constant rotation (60 rpm). The washing and staining procedure was performed in the Affymetrix Fluidics Station. The probe array was exposed to 10 washes in 6× SSPE-T at 25°C followed by 4 washes in 0.5× SSPE-T at 50°C. The biotinylated cRNA was stained with a streptavidin-phycoerythrin conjugate (10 µg/ml; Molecular Probes, Eugene, OR) in 6× SSPE-T for 30 min at 25°C followed by 10 washes in 6× SSPE-T at 25°C. The probe arrays were scanned at 560 nm using a confocal laser-scanning microscope with an argon ion laser as the excitation source (Hewlett Packard GeneArray Scanner G2500A). The readings from the quantitative scanning were analyzed by the Affymetrix Gene Expression Analysis software. . These estimates formed the basis for statistical testing.
Color display of gene expression
Differential expression was determined of the combined basis of statistical testing using ttest and on the basis of ratio with a cut-off of p<0.05 and fold ≥ 2 being called positive for differential expression. Genes passing this filter were allocated to four mutually exclusive groups according to their expression pattern. Hierarchical clustering was performed as follows. Genes were selected according criteria described in the text. For the selected genes, expression indexes were transformed across samples to an N (0,1) distribution using a standard statistical Z-transform. These values were input to the GeneCluster program of Eisen (15) and genes were clustered using average linkage and correlation dissimilarity.
Signal transduction pathways, metabolic pathways and other functional groupings of genes were evaluated for differential regulation using the visualization tool GenMAPP (16) (UCSF, www.GenMAPP.org). Several pathway maps have been developed and additional maps were produced based on Science's Signal Transduction Knowledge Environment (www.stke.org). Genes were identified as important using this tool on the basis of how comprehensively a particular pathway was affected by a given treatment and on the basis of how many of the treatments produced a similar effect on specific genes. Identifying genes in this way helps to reduce false positive rates associated with analysis of thousands of genes without deleteriously elevating false-negative rates as often occurs when using purely statistical methods such as Bonferroni correction. To evaluate the reliability of the array results, Sixteen genes detected in the microarray assay were selected for further confirmation between Ha-ras wildtype and Haras mutant tumors, and between FTI treated and non-FTI treated tumors by semi-quantitative RT-PCR as previously described (17) .
To find FTI sensitive gene signatures, k-nearest neighbors (k-NN) algorithm was used to 8 FTI treated tumors with/ without Ha-ras mutation. Firstly, Neighborhood analysis was used to select gene markers which have expression patterns closely correlated with the Haras status. Then a series of competitive models were built with a wide range of features (1 to 200 gene markers). The predicting error rate of each of these models was estimated by using 'leave-one-out' cross-validation approach. Finally, the best model was chosen based on their predicting error rates. The obtained classifier was then used for predicting FTI sensitivity of the samples. GeneCluster 2.0 was used to perform these analyses.
Results:
Efficacy of R115777 in treatment of rat mammary tumors
In this experiment, we took animals with small to moderate sized mammary tumors and surgically removed a 100-200 mg specimen (Fig 1) . Interestingly, minimal bleeding was observed. The skin was closed with wound clips. Three days following this "biopsy" procedure, rats were treated with FTI (50 mg/kg BW/day for a period of 6 weeks). When one examined the results, it was observed that roughly 50% of tumors displayed rapid regression while most of the remaining tumors showed relatively indolent growth or partial regression. When we examined the Ha-ras mutation status, we found that 6/7 tumors that were Ha-ras mutation positive underwent complete regression (Fig 1B) . Among the Ha-ras mutation negative tumors, 2/8 underwent complete regressions (Fig. 1A) . However, virtually Based on previous studies with a variety of FTI inhibitors as well as our own data (see above) we had expected tumors with an Ha-ras mutation to be highly sensitive to the therapeutic effects of R115777. We therefore wished to determine whether an untutored genomic analysis could differentiate highly sensitive (Ha-ras positive) tumors from variably sensitive (Ha-ras negative) tumors prior to FTI treatment. Four Ha-ras positive tumors, four Ha-ras negative tumors and normal mammary epithelia were examined. The differences between tumors and normal epithelia were striking. Table 1 . When examining control or FTI treated tumors with a Ha-ras mutation, 398 genes were found differentially expressed (Table 2) 
Gene expression profile associated only with FTI treated rat mammary tumors contained an activated Ha-ras
As show in Figure 1 , the efficacy of FTI treatment against rat mammary tumors is greater in tumors with an activated Ha-ras when compared to those that did not contain an activated Ha-ras. We have generated gene expression profiles specific for tumors with an activated Ha-ras and those which did not contain an activated Ha-ras ( Figure 5A ). The expression data are shown in Table 2 . were systematically evaluated for differential regulation using the visualization tool GenMAPP. We imported our data set into the program and convert the expression data into illustrations demonstrating presence and significant expression change for the genes represented on the microarray based on the analysis of FTI treatment in Ha-ras wildtype tumors and Ha-ras mutant tumors. We found that genes in at least two major regulatory pathways were significantly altered during FTI treatment. We employed a modified therapeutic intervention to examine the efficacy of R115777 in this model. After a rat developed a palpable mammary tumor roughly a 100-200 mg piece of the lesion was removed. These surgical biopsies allow one to characterize the baseline tumor for various biological properties including Ha Ras status. Beginning three days following the biopsy, the rats were administered FTI (50 mg/kg BW/day) and tumor growth was determined by caliper measurements. As can be seen in Figure 1 simultaneously show differing responses to standard therapeutic treatments. In the case at hand we knew based on previous in vitro and in vivo studies that tumors with a Ha-ras mutation were likely to be highly susceptible to inhibition by FTI inhibitors. Therefore normal mammary epithelia and tumors with or without Ha-ras mutations were employed in an array analysis. In fact the tumors with a Ha-ras mutation could be clearly separated from the tumors with no Ha-ras mutation. This is quite striking since these tumors are all ER+ have a similar histopathology and all respond similarly to hormonal agents such as tamoxifen, aromatase inhibitors or dehydropepiandrosterone (13, 26, 27) . Thus our analysis may be useful to differentiate sensitivity to R115777 but did not differentiate sensitivity to agents such as tamoxifen, aromatase inhibitors or dehydropepiandrosterone since these agents were strikingly effective on tumors with or without a Ha-ras mutation. In Figure 2 & 4 we performed a tutored analysis examining genes expression patterns in Ha-ras positive and Ha-ras negative tumors. Certain of these genes are listed in Table 2 . Given that we knew a substantial amount about Ha-ras some of the genes which showed large differences in expression were unexpected. . In the present study using an Affymetrix microarray that contains about 8,000 genes and ESTs, we identied differentially expressed genes in rat mammary tumors and the modulating effects of R115777 on the gene expression. Our goals were to find genes whose expression is highly modulated by FTI treatment which may contribute to the efficacy of When one examines Table 2 particularly those genes whose expression is decreased primarily in Ha-ras positive but not in Ha-ras negative tumors one is struck by a number of genes involved in cell proliferation. These include enzymes directly involved in DNA replication e.g. PCNA, DNA polymerase alpha II subunit, topoisomerase 2 alpha as well as other genes involved in cell proliferation such as such as cdc 37 homolog and the mitogenic regulation SseCKS (322) gene. Striking decrease in expression of these genes is likely to reflect the fact that R115777 is profoundly effective in causing tumor regression in Ha-ras positive tumors. In fact we have observed a striking decrease in cell proliferation (>75% decrease at four days) assessed by BudR labeling in tumors with Ha-ras mutations following treatment with R115777 (Christov, K; Lubet, R. Unpublished Data). In contrast, similar treatment of non Ha-ras tumors had more limited and somewhat variable effects.
Presumably these gene expression changes are a reflection of the decreased proliferation and are not themselves the target molecules since they are not known to be prenylated. R115777 has profound effects on the modulation of genes whose expression was altered during tumorigenesis, and these genes may or may not be involved in the rat mammary tumorigenesis (Figure 2 & 4) . Table 2 lists some potential genes that involved in (29) . Overexpression of Ha-ras resulted in p53 posttranslation modifications at Ser33 and Ser46 (30) , which are the same sites that exhibited p38-dependent phosphorylation after UV radiation (29) . p53 is mutated resulting in protein stabilization and overexpression in many cancers including breast cancer. In addition to its transcriptional function, WT1 binds p53 to stabilize p53 and modulate transcriptional properties of WT1 and p53 (31, 32) .
In this study, we found that RasGRP1, RalGDS, ras homolog gene family member V, p38, p53, WT1 and Hsp70 were significantly modulated in tumors with Ha-ras activation after FTI treatment. FTI is known to affect ras-MAP kinase signaling cascade by blocking Previous study on pathways identification by microarray analysis in acute myeloid leukemia have shown that cell signaling, cytoskeletal organization, immunity, and apoptosis affected by R115777 (35) . By using the visualization tool GenMAPP, we also found that genes in at least three major regulatory pathways were significantly altered after FTI treatment. Although we do not know at present if there are significant differences in functions of these three pathways in the tumors that do and do not respond. We do show some of the genes in these pathways are differentially expressed in the tumors that do respond (with Ha-ras mutation) and those without Ha-ras mutation (Figures 6 and 7) . Finally, in Figure 6 the apoptotic pathway is presented. Defective apoptosis represents a major causative factor in the development and progression of cancer. The ability of tumor cells to evade engagement of apoptosis can play a significant role in their resistance to conventional therapeutic regimens. As we can see in the figure, several key apoptotic genes are involved in FTI treatment. Among them, specific genes such as c-jun, and c-myc which might be expected to be antiapoptotic were downregulated by FTI in Haras activated tumors, whereas , Bax, and TNFR1 were specially downregulated by FTI in tumors without Ha-ras activation. It may be difficult to discern clearly genes related to apoptosis in this in vivo system since even the exquisitely sensitive Ha-ras mutant bearing tumors demonstrated no more than 3% apoptotic cells, as defined by the TUNEL assay, following 4 days of treatment with R115777. We have specifically mentioned a limited number of genes whose expression were altered by FTI treatment however there are literally hundreds of genes whose expression was altered and which might turn out to be significant in determining the efficacy of this class of agents. Future studies should include the use of in an independent animal experiment to determine if gene clusters that identify different phenotypes are reproducible or predictive.
In summation, we have observed the following employing microarray analysis.
Firstly, we found that Ha-ras mutant tumors are particularly susceptible to R115777 and that this is paralleled by more striking effects on proliferation related genes in Ha-ras mutant tumors. Secondly, the greatest number of altered gene expression, following treatment with R115777, is common to both Ha-ras mutant and wild type tumors. These changes may prove to be both pharmacodynamic markers and give mechanistic insight into mechanisms of action. Thirdly, there appear to be genes which can discriminate Ha-ras mutant and Ha-ras Table 1 . Genes modulated by R115777 treatment regardless of the Ha-ras status of the tumors. Table 2 . Genes that found differentially expressed during rat mammary tumorigenesis were modulated back to normal levels by FTI treatment (from cluster a & c of Figure 4) . N1  N2  N3  N4  T1  T2  T3  T4  T1  T2  T3  T4 Non-FTI H-ras+ FTI H-ras+ Epithelium N1  N2  N3  N4  T1  T2  T3  T4  T1  T2  T3  T4 Non-FTI WT FTI WT Epithelium
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